DarioHealth (DRIO) Form 4: Matheis Granted 20,000 Restricted Shares, Vesting in Two Years
Rhea-AI Filing Summary
DarioHealth Corp. director Dennis Matheis reported a non‑derivative acquisition of company stock. On 09/11/2025 Mr. Matheis received a restricted share award of 20,000 shares at a reported price of $0. The award is scheduled to vest on the last day of the second anniversary after the grant date. Following the reported transaction, Mr. Matheis beneficially owned 27,631 shares, an amount that reflects a 20‑for‑1 reverse stock split effected on August 28, 2025. The Form 4 was signed on 09/15/2025.
Positive
- Director alignment: Awarded 20,000 restricted shares that vest over two years, aligning the director's interests with shareholders
- Transparent disclosure: Form 4 filed and signed on 09/15/2025, documenting the grant and post‑split ownership
Negative
- None.
Insights
TL;DR: Director received restricted equity; vesting schedule aligns incentives without immediate cash outlay.
The reported transaction shows a typical restricted share award to a director rather than a sale or open‑market purchase. The award price is $0, indicating a grant rather than a purchase, and it vests on the last day of the two‑year anniversary period, creating a time‑based retention incentive. The post‑transaction beneficial ownership figure incorporates a 20‑for‑1 reverse split, which is a corporate action that alters share counts but not ownership percentage absent other changes. This filing is routine corporate governance disclosure and does not by itself provide information on company performance or valuation.
TL;DR: Insider award increases director alignment but is immaterial alone for valuation.
The Form 4 reports a non‑cash grant of 20,000 restricted shares to a director on 09/11/2025 with vesting after two years. Such grants are commonly used to align directors with shareholder interests. The filing notes the 20‑for‑1 reverse split on August 28, 2025, which explains the reported 27,631 shares beneficially owned after the transaction. The disclosure is specific to ownership change and contains no financial performance metrics; its investor impact is likely minimal without additional context.